Literature DB >> 34751872

The Novel Tumor Microenvironment-Related Prognostic Gene AIF1 May Influence Immune Infiltrates and is Correlated with TIGIT in Esophageal Cancer.

Xiaoling Xu1,2,3, Ding Wang3, Na Li3, Jiamin Sheng1,2, Mingying Xie3, Zichao Zhou3, Guoping Cheng2,3,4, Yun Fan5,6,7.   

Abstract

BACKGROUND: Esophageal carcinoma (EC) is the sixth most common cause of cancer-related mortality worldwide. Studying the associations of the tumor microenvironment (TME) with pathology and prognosis would illustrate the underlying mechanism of prognostic prediction and provide novel targets for immunotherapy in the treatment of EC.
METHODS: Transcriptomic profiles of 159 EC patients were obtained from The Cancer Genome Atlas (TCGA) database. Stromal and immune scores were calculated using the ESTIMATE algorithm. Differentially expressed genes (DEGs) were identified by the optimal score cutoff. Functional enrichments were analyzed by DAVID, while prognostic genes were explored using the Kaplan-Meier method. Validation analysis was performed using immunohistochemistry in tissue microarrays containing samples from 145 EC patients. Multiplex immunofluorescence staining was performed to detect a panel of 6 immune markers, including T-cell immunoreceptor with Ig and ITIM domains (TIGIT), in 90 EC patients.
RESULTS: Immune scores significantly increased with increasing age, while stromal scores were dramatically elevated with increasing tumor stage. Fifteen TME-related DEGs including allograft inflammatory factor 1 (AIF1) were identified as prognostic factors of EC. Furthermore, the validation cohort indicated that AIF1 was negatively associated with the prognosis of esophageal squamous cell carcinoma patients. Subsequent analyses suggested that AIF1 may affect immune infiltrates, including T cells and natural-killer cells. Moreover, a correlation between AIF1 and TIGIT was identified.
CONCLUSIONS: These results indicate that the TME-related gene AIF1 is a promising predictor of prognosis and is related to immune infiltrates and TIGIT expression in EC. However, further mechanistic studies are needed.
© 2021. Society of Surgical Oncology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34751872     DOI: 10.1245/s10434-021-10928-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   4.339


  46 in total

1.  Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.

Authors:  Tanguy Y Seiwert; Barbara Burtness; Ranee Mehra; Jared Weiss; Raanan Berger; Joseph Paul Eder; Karl Heath; Terrill McClanahan; Jared Lunceford; Christine Gause; Jonathan D Cheng; Laura Q Chow
Journal:  Lancet Oncol       Date:  2016-05-27       Impact factor: 41.316

2.  Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment.

Authors:  Xingzhe Ma; Enguang Bi; Yong Lu; Pan Su; Chunjian Huang; Lintao Liu; Qiang Wang; Maojie Yang; Matthew F Kalady; Jianfei Qian; Aijun Zhang; Anisha A Gupte; Dale J Hamilton; Chengyun Zheng; Qing Yi
Journal:  Cell Metab       Date:  2019-04-25       Impact factor: 27.287

3.  Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival.

Authors:  Lei Tu; Renguo Guan; Hanting Yang; Yu Zhou; Weifeng Hong; Liheng Ma; Guangzhe Zhao; Min Yu
Journal:  Int J Cancer       Date:  2019-12-02       Impact factor: 7.396

Review 4.  The immune contexture in human tumours: impact on clinical outcome.

Authors:  Wolf Herman Fridman; Franck Pagès; Catherine Sautès-Fridman; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2012-03-15       Impact factor: 60.716

5.  Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.

Authors:  Takashi Kojima; Manish A Shah; Kei Muro; Eric Francois; Antoine Adenis; Chih-Hung Hsu; Toshihiko Doi; Toshikazu Moriwaki; Sung-Bae Kim; Se-Hoon Lee; Jaafar Bennouna; Ken Kato; Lin Shen; Peter Enzinger; Shu-Kui Qin; Paula Ferreira; Jia Chen; Gustavo Girotto; Christelle de la Fouchardiere; Helene Senellart; Raed Al-Rajabi; Florian Lordick; Ruixue Wang; Shailaja Suryawanshi; Pooja Bhagia; S Peter Kang; Jean-Philippe Metges
Journal:  J Clin Oncol       Date:  2020-10-07       Impact factor: 44.544

6.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

Review 7.  Cancer-associated fibroblasts in gastrointestinal cancer.

Authors:  Hiroki Kobayashi; Atsushi Enomoto; Susan L Woods; Alastair D Burt; Masahide Takahashi; Daniel L Worthley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-05       Impact factor: 46.802

Review 8.  Immunotherapy for Esophageal Squamous Cell Carcinoma.

Authors:  Takashi Kojima; Toshihiko Doi
Journal:  Curr Oncol Rep       Date:  2017-05       Impact factor: 5.075

Review 9.  Tumor Immune Microenvironment and Immune Checkpoint Inhibitors in Esophageal Squamous Cell Carcinoma.

Authors:  Yoshifumi Baba; Daichi Nomoto; Kazuo Okadome; Takatsugu Ishimoto; Masaaki Iwatsuki; Yuji Miyamoto; Naoya Yoshida; Hideo Baba
Journal:  Cancer Sci       Date:  2020-06-24       Impact factor: 6.716

10.  Stromal microenvironment promoted infiltration in esophageal adenocarcinoma and squamous cell carcinoma: a multi-cohort gene-based analysis.

Authors:  Jiali Li; Zihang Zeng; Xueping Jiang; Nannan Zhang; Yanping Gao; Yuan Luo; Wenjie Sun; Shuying Li; Jiangbo Ren; Yan Gong; Conghua Xie
Journal:  Sci Rep       Date:  2020-10-29       Impact factor: 4.379

View more
  2 in total

Review 1.  Update in TIGIT Immune-Checkpoint Role in Cancer.

Authors:  Tiziana Annese; Roberto Tamma; Domenico Ribatti
Journal:  Front Oncol       Date:  2022-05-17       Impact factor: 5.738

2.  Global research trend of esophageal squamous cell carcinoma from 2012 to 2022: a bibliometric analysis.

Authors:  Zehua Zhang; Zhuyun Leng; Kang Fang; Mingchuang Sun; Zhaoxing Li; Le Kang; Tao Chen; Meidong Xu
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.